Crossref
Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation
ACTA Pharmaceutica Sciencia · 2026 · 64 (2) · 259
DOI: 10.23893/1307-2080.aps64015 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACTA Pharmaceutica Sciencia, 2026. Verfasst von Areej W. Alhagiesa und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Alhagiesa, A. W., & Ghareeb, M. M. (2026). Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation. ACTA Pharmaceutica Sciencia, 64(2), 259. https://doi.org/10.23893/1307-2080.aps64015
Vancouver
Alhagiesa AW, Ghareeb MM. Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation. ACTA Pharmaceutica Sciencia. 2026;64(2):259. doi:10.23893/1307-2080.aps64015
BibTeX
@article{Alhagiesa2026,
author = {Alhagiesa, Areej W. and Ghareeb, Mowafaq M.},
title = {Formulation of bortezomib human serum albumin nanoparticles, in vitro and in vivo evaluation},
journal = {ACTA Pharmaceutica Sciencia},
year = {2026},
volume = {64},
number = {2},
pages = {259},
doi = {10.23893/1307-2080.aps64015}
}
EUVIMED